Dr. Reddy's plots new assault on U.S. market

Indian drugmaker Dr. Reddy's Laboratories plans to launch about seven new generics in the United States this year and next, including its version of AstraZeneca's reflux drug Prilosec, a company official said in an interview with Reuters. Report

Suggested Articles

Olumiant
Marketing

Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

by Kyle Blankenship
Manufacturing

Krystal Biotech investing $10M on facility for gene therapies

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

by Eric Palmer
AbbVie
Pharma Asia

AbbVie donates $1M-plus of HIV drug for deadly coronavirus

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.

by Angus Liu